Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients
Immunovant (Nasdaq: IMVT) has revealed promising six-month remission data for batoclimab in treating uncontrolled Graves' disease. In a proof-of-concept study, approximately 80% (17/21) of patients maintained normal thyroid function six months after treatment cessation, with 50% (8/17) of responders achieving anti-thyroid drug (ATD) free remission.
The study involved a 24-week treatment period with batoclimab administered subcutaneously, followed by a 24-week off-treatment follow-up. The treatment demonstrated strong durability, with an additional 30% (5/17) of responding patients requiring only minimal ATD doses. Safety and tolerability were consistent with previous batoclimab studies.
Two potentially registrational trials for IMVT-1402, the company's lead compound, are currently enrolling patients, with topline results expected in 2027.
Immunovant (Nasdaq: IMVT) ha reso noti promettenti dati di remissione a sei mesi per batoclimab nel trattamento della malattia di Graves non controllata. In uno studio proof-of-concept, circa 80% (17/21) dei pazienti ha mantenuto una funzione tiroidea normale sei mesi dopo la sospensione del trattamento, con il 50% (8/17) dei responder che ha raggiunto la remissione senza farmaci antitiroidei (ATD).
Lo studio prevedeva un periodo di trattamento di 24 settimane con somministrazione sottocutanea di batoclimab, seguito da un follow-up off-treatment di 24 settimane. Il trattamento ha mostrato buona durabilità: un ulteriore 30% (5/17) dei pazienti responder ha richiesto solo dosi minime di ATD. Sicurezza e tollerabilità sono risultate in linea con gli studi precedenti su batoclimab.
Due studi potenzialmente registrativi per IMVT-1402, il composto principale della compagnia, stanno attualmente arruolando pazienti, con risultati topline attesi nel 2027.
Immunovant (Nasdaq: IMVT) ha anunciado datos prometedores de remisión a seis meses para batoclimab en el tratamiento de la enfermedad de Graves no controlada. En un estudio proof-of-concept, aproximadamente el 80% (17/21) de los pacientes mantuvo una función tiroidea normal seis meses después de suspender el tratamiento, y el 50% (8/17) de los respondedores logró la remisión sin fármacos antitiroideos (ATD).
El estudio incluyó un periodo de tratamiento de 24 semanas con batoclimab administrado por vía subcutánea, seguido de 24 semanas de seguimiento sin tratamiento. El tratamiento demostró buena durabilidad: un adicional 30% (5/17) de los pacientes respondedores necesitó solo dosis mínimas de ATD. La seguridad y tolerabilidad fueron consistentes con estudios previos de batoclimab.
Dos ensayos potencialmente registratorios para IMVT-1402, el compuesto principal de la compañía, están actualmente reclutando pacientes, con resultados topline esperados en 2027.
Immunovant (Nasdaq: IMVT)는 통제되지 않는 그레이브스병 치료에서 바토클리맙의 6개월 완화(remission) 결과가 유망하다고 발표했습니다. 개념증명(proof-of-concept) 연구에서 약 80% (17/21)의 환자가 치료 중단 6개월 후 정상 갑상선 기능을 유지했으며, 반응군 중 50% (8/17)는 항갑상선제(ATD) 없이 완화에 도달했습니다.
본 연구는 바토클리맙을 피하주사로 투여하는 24주 치료 기간과 그 후 24주간의 무치료 추적 관찰로 구성되었습니다. 치료는 내구성이 강하게 나타났고, 추가로 반응 환자 중 30% (5/17)는 최소한의 ATD 용량만 필요했습니다. 안전성 및 내약성은 이전 바토클리맙 연구와 일치했습니다.
회사의 주력 물질인 IMVT-1402에 대한 잠재적 허가 임상 2건이 현재 환자 모집 중이며, 주요 결과는 2027년에 발표될 예정입니다.
Immunovant (Nasdaq: IMVT) a dévoilé des données prometteuses de rémission à six mois pour le batoclimab dans le traitement de la maladie de Basedow non contrôlée. Dans une étude proof-of-concept, environ 80% (17/21) des patients ont maintenu une fonction thyroïdienne normale six mois après l'arrêt du traitement, et 50% (8/17) des répondeurs ont obtenu une rémission sans traitements antithyroïdiens (ATD).
L'étude comprenait une période de traitement de 24 semaines avec administration sous-cutanée de batoclimab, suivie d'un suivi sans traitement de 24 semaines. Le traitement a montré une bonne durabilité : 30% (5/17) supplémentaires des répondeurs n'ont eu besoin que de doses minimales d'ATD. La sécurité et la tolérance étaient conformes aux études antérieures sur le batoclimab.
Deux essais potentiellement d'enregistrement pour IMVT-1402, le composé principal de la société, recrutent actuellement des patients, avec des résultats topline attendus en 2027.
Immunovant (Nasdaq: IMVT) hat vielversprechende Daten zur sechsmonatigen Remission von Batoclimab bei der Behandlung der nicht kontrollierten Basedow-Krankheit veröffentlicht. In einer Proof-of-Concept-Studie behielten etwa 80% (17/21) der Patienten sechs Monate nach Abbruch der Behandlung eine normale Schilddrüsenfunktion; bei 50% (8/17) der Responder trat eine Remission ohne Schilddrüsenblocker (ATD) ein.
Die Studie umfasste eine 24-wöchige Behandlungsphase mit subkutan verabreichtem Batoclimab, gefolgt von einer 24-wöchigen Nachbeobachtung ohne Therapie. Die Behandlung zeigte eine gute Dauerwirkung: weitere 30% (5/17) der responder benötigten nur minimale ATD-Dosen. Sicherheit und Verträglichkeit entsprachen früheren Batoclimab-Studien.
Zwei potenziell registratorische Studien zu IMVT-1402, dem führenden Wirkstoff des Unternehmens, rekrutieren derzeit Patienten; Topline-Ergebnisse werden für 2027 erwartet.
- Strong durability with 80% of patients maintaining normal thyroid function 6 months post-treatment
- 50% of responding patients achieved complete ATD-free remission
- Additional 30% of responders required only minimal ATD doses
- First-ever potentially disease-modifying therapy for uncontrolled Graves' disease
- Consistent safety and tolerability profile
- Topline results for registrational trials not expected until 2027
- Study conducted with suboptimal step-down dosing design
Insights
Roivant's batoclimab shows remarkable off-treatment durability in Graves' disease, potentially transforming treatment paradigms with disease-modifying capabilities.
This data readout from Roivant's Immunovant subsidiary represents a potentially groundbreaking development in Graves' disease treatment. The most compelling aspect is the durability of response - approximately
The anti-thyroid drug (ATD) free remission in
The data is especially impressive considering these were previously uncontrolled patients who had failed standard ATD therapy. This targets a clear unmet need in the treatment landscape.
From a mechanistic perspective, FcRn blockade represents a novel approach in Graves' disease. By targeting the recycling of pathogenic autoantibodies rather than just managing symptoms, batoclimab addresses the autoimmune root of the condition.
Importantly, the company is now advancing IMVT-1402, their lead compound, in two potentially registrational trials with a consistent 600 mg dose rather than the step-down approach used with batoclimab. This optimization could potentially yield even stronger durability and remission rates.
The timeline for these trials, with topline readouts expected in 2027, provides a clear development pathway. If successful, this therapeutic approach could transform the standard of care for Graves' disease patients who currently face limited and often suboptimal treatment options.
- First-ever potentially disease-modifying therapy for uncontrolled Graves’ disease patients
- Of 21 patients who entered the six-month off-treatment follow-up period, ~
80% (17/21) demonstrated response, resulting in normal thyroid function (T3 and T4 less than the upper limit of normal) at the end of the six-month follow-up period - Of the 17 responders to therapy, ~
50% (8/17) achieved anti-thyroid drug (ATD) free remission at six months following end of batoclimab treatment - Two potentially registrational trials for IMVT-1402 in Graves’ disease are currently enrolling with topline readouts expected in 2027
- Roivant to host investor call to discuss these updates today, September 3, 2025, at 4:30 p.m. EDT
NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today shared an abstract with six-month off-treatment data in uncontrolled Graves’ disease (GD) patients treated with batoclimab for 24 weeks, to be presented at the 2025 Annual Meeting of the American Thyroid Association (ATA) on September 11, 2025.
“These novel and encouraging results support FcRn blockade as a potentially effective mechanism for the treatment of Graves’ disease, with the six-month remission data providing evidence of potential disease modification,” said George Kahaly, M.D., Ph.D., Lead Principal Investigator.
“We are incredibly excited to present these remission data demonstrating strong durability of response and ATD-free remission in previously uncontrolled patients off-treatment for six months,” said Eric Venker, M.D., Pharm.D., CEO of Immunovant. “We believe these data have the potential to be transformative for patients and practice-changing for physicians, if approved by FDA, by addressing a significant unmet need in Graves’ disease.”
Graves’ Disease Proof-of-Concept Study
Six-month off-treatment data was generated from a proof-of-concept study of batoclimab in Graves’ disease. Batoclimab is Immunovant’s first generation fully human monoclonal antibody targeting FcRn. The study included a 24-week treatment period with a dose step-down (Weeks 0-12 at 680 mg weekly (QW) subcutaneously (SC) and Weeks 12-24 at 340 mg QW SC), followed by a 24-week off-treatment follow-up period. The study included patients with active Graves’ disease as documented by presence of elevated thyrotropin receptor autoantibodies (TRAb) and hyperthyroid despite ATD therapy. The key endpoint of the study is the proportion of participants who achieve normalization of free triiodothyronine (T3) and free thyroxine (T4) or have T3 / T4 below the lower limit of normal (LLN) at Week 24, without an increase in ATD dose from baseline.
Graves’ Disease Six-month Remission Data
25 patients were enrolled in the treatment period with 21 patients entering the off-treatment 24-week follow-up period to be assessed for remission:
- At Week 48, or the end of the six-month follow-up period (patients off-treatment for 24 weeks), ~
80% (17/21) patients maintained T3/T4 values ≤ upper limit of normal (ULN), indicating strong durability of response through six months off treatment - Of these 17 patients, ~
50% (8/17) were in ATD free-remission and an incremental ~30% (5/17) were on ATD doses of 2.5 mg/day following six months off treatment, even with batoclimab’s suboptimal step-down dosing design during the treatment period - Safety and tolerability were observed to be consistent with prior batoclimab studies
IMVT-1402 Registrational Trial Design
Two potentially registrational trials of Immunovant’s lead compound IMVT-1402 in Graves’ disease will evaluate 600 mg dose for up to 52 weeks without a step-down in dose.
The two potentially registrational global trials for IMVT-1402 in Graves’ disease are currently enrolling with topline readouts expected in 2027.
Investor Conference Call Information
Roivant will host a live conference call and webcast at 4:30 p.m. EDT on Wednesday, September 3, 2025, to discuss these Immunovant data. To access the conference call by phone, please register online using this registration link. The presentation and webcast details are available under “Events & Presentations” in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant’s website after the conference call.
About Immunovant, Inc.
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com.
Forward-Looking Statements
This presentation contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "can," “may,” “might,” “will,” “would,” “should,” “expect,” “believe,” “estimate,” “design,” “plan,” "intend," "anticipate," and other similar expressions are intended to identify forward-looking statements. Such forward looking statements include Immunovant’s expectations regarding the clinical and therapeutic benefits of its product candidates, including durability of response, efficacy, tolerability and the potential for disease modification and first-in-class potential; patient enrollment, timing, design, progress, scope and results of its existing and planned clinical trials, including the potential registrational trials for IMVT-1402 in Graves’ disease and whether the trial designs will result in improved efficacy data; future development of IMVT-1402 and batoclimab, including the timing and likelihood of expansion into additional indications; the evolution of the treatment paradigm for Graves’ disease in North America; the size and growth of the potential markets for Immunovant's product candidates and indication selections, including any estimated market opportunities; expectations regarding the receipt of regulatory approval for its product candidates; and whether, if approved, IMVT-1402 or batcolimab will be successfully distributed, marketed or commercialized. All forward-looking statements are based on estimates and assumptions by Immunovant’s management that, although Immunovant believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Immunovant expected. Such risks and uncertainties include, among others: initial results or other preliminary analyses or results of early clinical trials may not be predictive of final trial results or of the results of later clinical trials; results of animal studies may not be predictive of results in humans; the timing and availability of data from clinical trials; the timing of discussions with regulatory agencies, as well as regulatory submissions and potential approvals; the continued development of Immunovant’s product candidates, including the timing of the commencement of additional clinical trials; Immunovant’s scientific approach, clinical trial design, indication selection, and general development progress; future clinical trials may not confirm any safety, potency, or other product characteristics described or assumed in this presentation; any product candidate that Immunovant develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; Immunovant’s product candidates may not be beneficial to patients, or even if approved by regulatory authorities, successfully commercialized; the effect of global factors such as geopolitical tensions and adverse macroeconomic conditions on Immunovant’s business operations and supply chains, including its clinical development plans and timelines; Immunovant’s business is heavily dependent on the successful development, regulatory approval and commercialization of batoclimab and IMVT-1402; Immunovant is in various stages of clinical development for IMVT-1402 and batoclimab; and Immunovant will require additional capital to fund its operations and advance IMVT-1402 and batoclimab through clinical development. These and other risks and uncertainties are more fully described in Immunovant’s periodic and other reports filed with the Securities and Exchange Commission (SEC), including in the section titled “Risk Factors” in Immunovant’s most recent Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the SEC on August 11, 2025, and Immunovant’s subsequent filings with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Immunovant undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
About Roivant
Roivant (Nasdaq: ROIV) is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. Beyond therapeutics, Roivant also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. For more information, visit https://roivant.com.
Roivant Forward-Looking Statements
This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are usually identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and variations of such words or similar expressions. The words may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act.
Our forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about the clinical and therapeutic potential of our product candidates, the availability and success of topline results from our ongoing clinical trials and any commercial potential of our product candidates following applicable regulatory approvals. In addition, any statements that refer to projections, forecasts or other characterizations of future events, results or circumstances, including any underlying assumptions, are forward-looking statements. Actual results may differ materially from those contemplated in these statements due to a variety of risks, uncertainties and other factors.
Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the Risk Factors section of our filings with the U.S. Securities and Exchange Commission. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts:
Investors
Keyur Parekh
keyur.parekh@roivant.com
Media
Stephanie Lee
stephanie.lee@roivant.com
FAQ
What are the key results from Immunovant's Graves' disease treatment study?
How is batoclimab administered to Graves' disease patients?
When will Immunovant's IMVT-1402 registrational trial results be available?
What makes Immunovant's treatment different from existing Graves' disease therapies?
What is the dosing protocol for the new IMVT-1402 registrational trials?
